NAMA
BCRX icon

Nikko Asset Management Americas’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nikko Asset Management Americas’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7K Buy
+2,575
New +$23.3K ﹤0.01% 273

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Nikko Asset Management Americas's BCRX Position: Q2 2026 in Review

Nikko Asset Management Americas opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 2,575 shares worth $25.7K. The stake represents ﹤0.01% of the portfolio and ranks #273 among its holdings.

318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Nikko Asset Management Americas held 2,575 shares of BioCryst Pharmaceuticals worth $25.7K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Nikko Asset Management Americas position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Nikko Asset Management Americas's portfolio in Q2 2026, its #273 holding.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.